Biotech Values

[vinmantoo]

Yee calculates that the combined market capitalization of all the biotech stocks valued at under $5 billion is around $350 billion. The cash balance of the top 20 biopharma companies combined, meanwhile, is over $300 billion.

That is an absolutely stunning statistic. Since interest rates are rising I could see big pharma accelerating their M&A plans if they want to use debt to finance purchases rather that deplete their cash stockpiles. Well, at least for major buys.